Sunitinib Non Small Cell Lung Cancer Patients Over 70

Exclusion Criteria

• •Has predominantly squamous NSCLC histology.
• •Had prior treatment with study drugs or other drugs.
• •Has a history of hypersensitivity to any component of the study drug. Has any evidence of an of antecedent hemoptysis, squamous histology, or ongoing anticoagulation or clotting diathesis.
• •Pre-existing hemoptysis Grade 2, cavitating lesions or clear proximity or involvement of blood vessels.
• •Has had major surgery or radiation therapy within 4 weeks of starting the study treatment.
• •Has had NCI CTCAE (Version 3.0) Grade 3-4 hemorrhage within 4 weeks of starting the study treatment.
• •Has a history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan; however, treated, stable, and asymptomatic brain metastases are allowed.
• •Has had any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. Has ongoing cardiac dysrhythmias of NCI CTCAE (Version 3.0) Grade 2.
• •Has prolonged QTc interval on baseline EKG. Has uncontrolled hypertension.
• •Has pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
• •Is receiving concurrent treatment on another clinical trial.
• •Supportive care trials or non-treatment trials, (eg, QOL), are allowed.
• •Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.
• •Is receiving concurrent investigational therapy or has received such therapy within the past 30 days.
• •Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.
• •Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.
• •Is unable to comply with requirements of study